News

A shorter duration of adrenal insufficiency — when the adrenal gland is not working properly — after surgical removal of a pituitary tumor may predict recurrence in Cushing’s disease patients, a new study suggests. The study, “Recovery of the adrenal function after pituitary surgery in patients with Cushing Disease:…

Tumors located outside the pituitary gland that produce the adrenocorticotropic hormone (ACTH) may cause, on rare occasions, cyclic Cushing’s syndrome — when cortisol levels show substantial fluctuations over time. That finding, based on the case of a patient with ACTH-secreting lung cancer,  is found in the study, “Cyclic Cushing’s syndrome caused…

Signifor (pasireotide) — a treatment approved for Cushing’s disease patients who are not cured by surgery — reduces the growth of pituitary tumor cells by lowering the amount of activated ERK1/2 proteins, a study finds. The treatment also induces programmed cell death, the scientists discovered. The study, “…

A patient’s age, urinary-free cortisol (UFC) level, fasting glucose — a measure of insulin resistance — body mass index (BMI), and the number of comorbidities at diagnosis for Cushing’s syndrome predicted the number of long-term comorbidities several years after remission, according to a study. Specifically, older age, lower baseline UFC,…

Transsphenoidal surgery — a minimally invasive surgery for removing pituitary tumors in Cushing’s disease patients — is also effective in children and adolescents with the condition, leading to remission with a low rate of complications, a study reports. The research, “Neurosurgical treatment of Cushing disease in pediatric patients:…

A simple test that measures free cortisol levels in saliva at midnight — called a midnight salivary cortisol test — showed good diagnostic performance for Cushing’s syndrome among a Chinese population, according to a recent study. The test was better than the standard urine free cortisol levels and may be…

Corcept Therapeutics has received notice that it will be issued a new patent in the U.S. covering the use of Korlym (mifepristone), in combination with strong CYP3A inhibitors, to treat patients with Cushing’s syndrome. Upon issuance from the U.S. Patent and Trademark Office, the company plans to add…

A man with Cushing’s disease — caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma — who later developed metastases in the central nervous system without Cushing’s recurrence, was successfully treated over eight years with radiation and chemotherapy, according to a case report. The report, “Long-term survival…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

Patients with Cushing’s syndrome showed less abdominal fat and increased muscle mass, as well as reduced use of medications one year after having their adrenal glands removed, according to a new study. The research, “Changes of computed tomography-based body composition after adrenalectomy in patients with endogenous hypercortisolism,” was…